EMEA-000669-PIP01-09-M02
Key facts
| Invented name |
Humenza
|
| Active substance |
Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0022/2019
|
| PIP number |
EMEA-000669-PIP01-09-M02
|
| Pharmaceutical form(s) |
Suspension and emulsion for injection
|
| Condition(s) / indication(s) |
Prevention of influenza
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Sanofi Pasteur SA
E-mail: Piplan@sanofipasteur.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000669-PIP01-09-M02
|
| Compliance opinion date |
26/04/2019
|
| Compliance outcome |
positive
|